PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Impact of [18F]PSMA-1007 PET/CT Comparative to [18F]FLUOROCHOLINE PET/CT on Treatment Decision for Prostate Cancer Patient on Biological Recurrence: A Multicentric Prospective Observational Study
Version 1
: Received: 7 November 2023 / Approved: 8 November 2023 / Online: 8 November 2023 (10:30:04 CET)
How to cite:
FEVRIER, A.; Bouron, C.; De Vries, M.; Medhioub, O.; Lacoeuille, F.; Mention, P. Impact of [18F]PSMA-1007 PET/CT Comparative to [18F]FLUOROCHOLINE PET/CT on Treatment Decision for Prostate Cancer Patient on Biological Recurrence: A Multicentric Prospective Observational Study. Preprints2023, 2023110538. https://doi.org/10.20944/preprints202311.0538.v1
FEVRIER, A.; Bouron, C.; De Vries, M.; Medhioub, O.; Lacoeuille, F.; Mention, P. Impact of [18F]PSMA-1007 PET/CT Comparative to [18F]FLUOROCHOLINE PET/CT on Treatment Decision for Prostate Cancer Patient on Biological Recurrence: A Multicentric Prospective Observational Study. Preprints 2023, 2023110538. https://doi.org/10.20944/preprints202311.0538.v1
FEVRIER, A.; Bouron, C.; De Vries, M.; Medhioub, O.; Lacoeuille, F.; Mention, P. Impact of [18F]PSMA-1007 PET/CT Comparative to [18F]FLUOROCHOLINE PET/CT on Treatment Decision for Prostate Cancer Patient on Biological Recurrence: A Multicentric Prospective Observational Study. Preprints2023, 2023110538. https://doi.org/10.20944/preprints202311.0538.v1
APA Style
FEVRIER, A., Bouron, C., De Vries, M., Medhioub, O., Lacoeuille, F., & Mention, P. (2023). Impact of [18F]PSMA-1007 PET/CT Comparative to [18F]FLUOROCHOLINE PET/CT on Treatment Decision for Prostate Cancer Patient on Biological Recurrence: A Multicentric Prospective Observational Study. Preprints. https://doi.org/10.20944/preprints202311.0538.v1
Chicago/Turabian Style
FEVRIER, A., Franck Lacoeuille and Pierre-Jean Mention. 2023 "Impact of [18F]PSMA-1007 PET/CT Comparative to [18F]FLUOROCHOLINE PET/CT on Treatment Decision for Prostate Cancer Patient on Biological Recurrence: A Multicentric Prospective Observational Study" Preprints. https://doi.org/10.20944/preprints202311.0538.v1
Abstract
Purpose: Prostate cancer is the most common male prevalent malignancy in Europe. Biological recurrence occurs in 20-40% of patients within 10 years following treatment. [18F]F-Choline PET/CT is the most used technique for detecting recurrent disease but is rarely positive for low PSA levels. [18F]PSMA-1007 PET/CT allows early detection of recurrence sites.
Methods: We conducted a prospective multicenter study. Each patient had access to a [18F]F-Choline and [18F]PSMA PET/CT. The primary endpoint was to determine the therapeutic impact of the [18F]PSMA comparative to [18F]F-Choline PET/CT. Secondary endpoints were the diagnostic performance and the correlation between PET/CT parameters and prognostic factors of prostate disease.
Results: 47 patients were included. A therapeutic modification was observed in 36% of them between what the clinicians expected after the [18F]F-Choline PET/CT and what they finally decided after the [18F]PSMA PET/CT. Diagnostic performance of [18F]F-Choline was 28% versus 70% for [18F]PSMA with a significant difference. With [18F]PSMA PET/CT, there was a significative correlation between PSA level of biological recurrence and SUVmax but not between ISUP score and SUVmax of the selected lesion.
Conclusion: This study found a modification in therapeutic management following [18F]PSMA PET/CT in one third of patients. This change could result in earlier and better management with detection of lesions at a lower PSA level than is possible with [18F]F-Choline.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
